Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. Its lead clinical candidate in oncology is eftilagimod alfa, a proprietary soluble LAG-3 protein and MHC Class II agonist that activates the immune system to fight cancer. In autoimmune diseases, Immutep's IMP761 is the world's first LAG-3 agonist antibody designed to target the underlying causes of autoimmune diseases. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. For more information, please visit www.immutep.com.
Company Details
- Employees
- 52
- Address
- Level 33, Australia Square 264 George Street, Sydney,nsw 2000,australia
- Phone
- 33169289992
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- immutep.com
- HQ
- Sydney, NSW
Immutep Limited Questions
Immutep Limited's helpline number is 33169289992
Immutep Limited's website is immutep.com
Immutep Limited's LinkedIn profile is https://au.linkedin.com/company/immutep-ltd
Immutep Limited has
52 employees.
View email and phone details for 52
employees at Immutep Limited.
Immutep Limited's industry is
Biotechnology Research
Immutep Limited's top competitors are
Neuren Pharmaceuticals Limited,
Prescient Therapeutics,
Telix Pharmaceuticals Limited,
Inoviq Ltd (Asx:iiq),
Piper Alderman,
Myrio Tx,
Immutep,
Ausbiotech,
Noxopharm Limited,
Imugene Limited.
Immutep Limited's categories are Biotechnology Research
